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Strengths and limitations of this study
 ► This systematic review and meta- analysis of ran-
domised controlled trials offers new information 
on the efficacy of mobile device apps in supporting 
medication adherence across a range of medical 
conditions.
 ► This review is reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses statement.
 ► A sensitive search strategy was designed, and 
screening of articles and data extraction were per-
formed independently by one clinical researcher and 
one non- clinical researcher.
 ► The review protocol was prospectively registered, 
and the scope of the review, inclusion and exclusion 
criteria remained unchanged throughout.
 ► Two reviewers independently considered the ab-
stracts and full- text articles for inclusion, extracted 
the data, and assessed the included studies for risk 
of bias in the same way.
ABSTRACT
Objectives To estimate the efficacy of app- based 
interventions designed to support medication adherence 
and investigate which behaviour change techniques (BCTs) 
used by the apps are associated with efficacy.
Design Systematic review of randomised controlled trials 
(RCTs), with meta- analysis.
Setting Medline/PubMed, PsycINFO, Cumulative Index to 
Nursing and Allied Health Literature, Embase and Web of 
Science were searched from 1990 to November 2018 for 
RCTs conducted in any healthcare setting.
Participants Studies of participants of any age taking 
prescribed medication for any health condition and for any 
duration.
Intervention An app- based intervention delivered through 
a smartphone, tablet computer or personal digital assistant 
to help, support or advise about medication adherence.
Comparator One of (1) usual care, (2) a control app which 
did not use any BCTs to improve medication adherence or 
(3) a non- app- based comparator.
Primary and secondary outcome measures The 
primary outcome was the pooled effect size of changes in 
medication adherence. The secondary outcome was the 
association between BCTs used by the apps and the effect 
size.
Results The initial search identified 13 259 citations. 
After title and abstract screening, full- text articles of 83 
studies were screened for eligibility. Nine RCTs with 1159 
recruited participants were included. The mean age of 
participants was >50 years in all but one study. Health 
conditions of target populations included cardiovascular 
disease, depression, Parkinson’s disease, psoriasis 
and multimorbidity. The meta- analysis indicated that 
patients who use mobile apps to support them in taking 
medications are more likely to self- report adherence to 
medications (OR 2.120, 95% CI 1.635 to 2.747, n=988) 
than those in the comparator groups. Meta- regression of 
the BCTs did not reveal any significant associations with 
effect size.
Conclusions App- based medication adherence 
interventions may have a positive effect on patient 
adherence. Larger scale studies are required to further 
evaluate this effect, including long- term sustainability, 
and intervention and participant characteristics that are 
associated with efficacy and app usage.
Prospero registration number PROSPERO Protocol 
Registration Number: CRD42017080150.
InTRODuCTIOn
Adherence to medication is defined as the 
extent to which patients take medications 
as prescribed and agreed with their health-
care providers.1 The therapeutic benefit of 
prescribed medications is limited owing to 
an estimated 50% of patients not adhering 
to medications.2 The annual cost of non- 
adherence is estimated to exceed £930 
million in England3 and between $100 and 
$300 billion in the USA.4 Furthermore, in 
2003 the Adherence to Long- term Therapies 
report published by the WHO stated that 
unless medication adherence is addressed, 
advances in biomedical technology will not 
achieve their potential.5
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Interventions for improving adherence should be reli-
able, contemporary, acceptable and readily available to 
the person. Mobile devices can meet these needs, and in 
2018 Ofcom reported that 78% of adults and 95% of indi-
viduals aged 16–24 years old in the UK own a smartphone, 
demonstrating that smartphones are a growing part of 
modern life.6 Patients who are prescribed multiple medi-
cations are commonly in the older age group, where the 
percentage of smartphone users may be lower. However, 
smartphone ownership in those aged over 65 more than 
trebled between the years 2012 and 2015 from 5% to 
18%, and is set to continue to increase.7
Hundreds of apps are now available to patients to 
support them in taking regular medication.8 Such apps 
frequently use behaviour change techniques (BCTs) 
to promote improvements in adherence. A BCT is 
defined as an active component of an intervention that 
is designed to change behaviour.9 To date, the efficacy 
of smartphone apps in supporting patient adherence to 
regularly prescribed medications has not been evaluated 
within the scientific literature using rigorous quantitative 
review. We have performed a novel systematic review with 
meta- analysis to evaluate the efficacy of smartphone apps 
in supporting medication adherence.
The objectives of this review are (1) to establish 
whether apps designed to support medication adherence 
demonstrate efficacy and (2) to identify the intervention 
characteristics and BCTs associated with efficacy. The 
conclusions drawn have potential to inform future large- 
scale public health interventions for the improvement of 
medication adherence.
MeThODS
This systematic review is reported according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses statement.10 The protocol for this review is 
registered with and published on the PROSPERO (Inter-
national Prospective Register of Systematic Reviews) 
database of systematic reviews.11 The scope of the review, 
inclusion and exclusion criteria remained unchanged 
throughout.
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study design 
and were not consulted to develop patient- relevant 
outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
Data sources
Medline/PubMed, PsycINFO, Cumulative Index to 
Nursing and Allied Health Literature, Embase and Web 
of Science electronic databases were searched from 
1990 to November 2018. A sensitive search strategy was 
designed based on preliminary searches, relevant papers 
and keywords. Key search terms included adherence, 
non- adherence, smartphone app and randomised 
controlled trials (RCTs). An example detailed search 
strategy for the Medline/PubMed database can be found 
in online supplementary etext 1. The reference lists of 
the included studies were screened for additional rele-
vant trials.
Two reviewers (LCA and AK) independently screened 
all citations by title and abstract and excluded those which 
were irrelevant or clearly did not meet the eligibility 
criteria. Full- text articles were obtained for all remaining 
citations and screened against the eligibility criteria by 
the same reviewers. Any discrepancies at any stage in 
the screening process were settled through discussion 
between LCA, AK and a third reviewer (SS).
Study selection
RCTs relevant to this review were those that investigated 
the use of an app on a mobile device to support medi-
cation adherence. The inclusion criteria were as follows:
 ► Participants of any age who were taking one or more 
prescribed medications for any health condition and 
for any duration.
 ► An intervention group which received an app- based 
intervention delivered through a smartphone, tablet 
computer or personal digital assistant to help, support 
or advise about medication adherence.
 ► A comparator group which received usual care, a 
control condition which did not use an app12 or a 
control app which did not include any BCTs (eg, an 
app that was a non- health- related game13).
 ► Medication adherence data were reported for both 
the intervention and comparator groups.
The exclusion criteria were as follows:
 ► Complex interventions of which an app was just one 
component.
 ► Interventions delivered by text messaging or 
telemedicine.
 ► Outcome assessed was adherence to treatment compo-
nents other than prescribed medication. For example, 
one study reported outcome data as a composite 
score, combining adherence to other aspects of the 
medical regimen (such as clinic attendance and labo-
ratory work) with adherence to medication.14
 ► A study population of healthy recruits who were 
required to adhere to a placebo medication.
 ► Comparator group received an adherence interven-
tion in another format, such as a different medication 
adherence app.
Published articles were required to be in the English 
language.
Data extraction and synthesis
Data were extracted independently by two reviewers 
(LCA and AK) using a custom data extraction form. 
Participants’ baseline characteristics were extracted, 
including age and sex. Raw data on medication adher-
ence were extracted either from the published articles 
or by contacting the authors of the primary studies by 
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Figure 1 PRISMA flow chart. PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses; RCT, 
randomised controlled trial.
email. When two measures of adherence were reported, 
that which was considered most comparable with the 
outcome measures of the other included studies was 
used for meta- analysis. For example, one study reported 
adherence according to both the number of times an 
electronically chipped dispenser was actioned by the 
patient and the weight of the dispensing canister at study 
follow- up, and the reviewers agreed that the action of 
dispensing was more comparable with that of the other 
included studies.15 Authors were contacted by email for 
any other data required which were not available in the 
published articles. Where more than one app interven-
tion was tested, data for the intervention considered 
most comparable with the other studies were extracted 
for meta- analysis. For example, one study investigated a 
‘basic app’ (which provided a unidirectional once- daily 
reminder) as well as an ‘advanced app’ (which provided 
customisable and interactive features) versus usual care.16 
The reviewers agreed that the advanced app was most 
comparable with the interventions of the other studies 
and so data pertaining to this intervention were extracted. 
BCTs that were used in the app- based interventions were 
coded according to the Behaviour Change Technique 
Taxonomy.17 This is a structured taxonomy of techniques 
used by interventions to change behaviour. The BCT 
taxonomy does not have a code relating to performance 
of behaviour, and therefore where participants were 
required to enter whether or not medication was taken, 
this was coded as ‘Report whether or not the behaviour 
was performed’. Similarly, the taxonomy does not have a 
code relating to tailoring of an intervention, and there-
fore where a study used information gained about a 
person to define the content, frequency or format of an 
intervention, this was coded as a ‘Tailored’ intervention.18
The included trials were assessed for risk of bias using 
the Cochrane Risk of Bias Tool.19 Two reviewers (LCA 
and AK) individually assessed each of the included arti-
cles against the criteria outlined in the tool. Any discrep-
ancies at any stage in the coding process were settled 
through discussion between the three reviewers (LCA, 
AK, SS). Studies were considered to be at unclear risk of 
bias for an item when the primary article did not provide 
sufficient information for the reviewers to decide categor-
ically between high or low risk of bias.
Statistical analysis
Outcome data on medication adherence were extracted 
from each of the included studies at the final observa-
tion point. Authors were contacted for raw final obser-
vation point adherence data if these were not reported 
in published manuscripts. Trials were considered homo-
geneous based on the content of the intervention and 
comparator groups and the outcome measurement 
of medication adherence. The Comprehensive Meta- 
Analysis Software20 was used to estimate the overall effect 
of app- delivered interventions on medication adherence 
using a random- effects model and to perform meta- 
regression using the BCTs used by the apps. The Compre-
hensive Meta- Analysis Software conversion function was 
used where required to convert extracted raw data into 
OR and standardised mean difference between the inter-
vention and control groups.21 The I2 statistics were used 
to estimate heterogeneity between the included studies.
ReSulTS
The initial electronic database search identified 13 259 
potentially eligible studies, and 2 were identified from the 
reference lists of identified articles. After removal of dupli-
cates, 9971 citations were screened by title and abstract. 
We considered 83 of these to be eligible and retrieved the 
full- text articles. Of these, nine studies reported outcome 
data eligible for meta- analysis.12 13 15 16 22–26 The screening 
process and reasons for exclusion are reported in figure 1.
The characteristics of the nine studies are shown in 
table 1. Publication year of the included studies ranged 
from 2014 to 2018. The median sample size was 102 
participants (range 24–412), and the median follow- up 
period was 12 weeks (range 28 days–16 weeks).
The mean age of participants in the intervention group 
was reported by eight studies and ranged from 20.3 
(SD 4.0)22 to 73.8 (SD 8)12; the mean of the mean ages 
across these eight studies was 56.7 years. One study did 
not report the mean age but presented the percentage 
of participants whose age fell within a series of band-
widths.15 The percentage of participants in the inter-
vention groups who were female ranged from 11%16 to 
89%,22 and the mean percentage of female participants 
among the included studies was 45.2%.
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Health problems of the target population varied 
between studies. Five studies sampled a patient popula-
tion with cardiovascular disease,12 13 16 23 26 and each of 
the remaining four studies enrolled patient populations 
with different health problems: depression,22 Parkinson’s 
disease,24 psoriasis15 and multimorbidity.25
Outcome measurement methods
A number of measures of medication adherence were 
used in the included studies. Of the nine studies, four 
measured adherence using the eight- item Morisky Medi-
cation Adherence Scale,24 26 27 with one of these also 
measuring adherence through a medication possession 
ratio (see online supplementary material).13 For this 
study, the Morisky Medication Adherence Scale data were 
extracted for the meta- analysis as these were most compa-
rable with the data available for other studies. A further 
study measured adherence using the four- item Morisky 
Medication Adherence Scale.25 Of the remaining studies, 
two reported adherence according to pill count,22 23 one 
the A14 self- report scale of medication adherence12 and 
one through a digital chip record fitted within the medi-
cation dispenser (table 1).15
Meta-analysis
Meta- analysis was performed, pooling results from the 
nine eligible studies which reported data on 988 partici-
pants, to estimate the effect of mobile apps in improving 
medication adherence.12 13 15 16 22–26 The results of this 
meta- analysis indicated that patients who participated in 
medication adherence interventions delivered by mobile 
apps were more likely to adhere to prescribed medications 
(OR 2.120, 95% CI 1.635 to 2.747) than those who did not 
use such interventions. The I2 value was 9.8, indicating 
low statistical heterogeneity between the studies included 
in the meta- analysis. The forest plot of the meta- analysis is 
shown in figure 2. The weighting of each individual study 
in the meta- analysis can be seen in online supplementary 
etable 1, and raw data extracted for the meta- analysis can 
be found in online supplementary etable 2.
A focused meta- analysis was performed, pooling 
results from the five studies which reported medication 
adherence according to the Morisky Medication Adher-
ence Scale.13 16 24–26 The results of this also indicated 
that patients using medication adherence interventions 
delivered by mobile apps reported higher adherence to 
prescribed medications (OR 1.83, 95% CI 1.42 to 2.36).
Behaviour change techniques
The most common BCT used by apps was ‘Tailored’, 
which was used by all studies. The next most common was 
‘Prompts and Cues’, used by seven studies,12 15 16 22–25 and 
‘Report whether or not the behaviour was performed’, 
which was used by six studies.12 16 22–25 Information on the 
BCTs coded for each of the interventions and the defini-
tions of each of the BCTs are available in online supple-
mentary etable 3 and 4. Agreement between reviewers 
for classification of BCTs used by the interventions was 
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Figure 2 Forest plot of randomised trials evaluating a mobile device app to support medication adherence against 
comparators.
assessed using the kappa statistics. This revealed a ‘very 
good’ level of agreement (kappa=0.902, 95% CI 0.835 to 
0.969). All BCTs coded for each of the study interventions 
are provided in online supplementary etable 3. Those 
coded in more than three but less than six of the nine 
studies were included in the meta- regression; this did not 
reveal any significant associations between the BCTs used 
and the effect size.
Risk of bias at primary study level
A summary of the risk of bias analysis is shown in table 2. 
Overall, all studies were deemed as unclear in their risk 
of bias.
The most common source of risk of bias among the 
studies was the absence of blinding of participants and 
personnel to the outcome measure. The second most 
common risk of bias arose from a lack of objective 
measurements of medication adherence. This was due to 
the use of self- report measures of adherence: six of the 
studies included in the meta- analysis reported adherence 
based on a self- assessment scale,12 13 16 24–26 and one study 
each used patient- entered medication logs in an app,22 an 
electronically chipped medicated foam dispenser15 and 
pill counts at clinic visits.23
Self- assessment scales are a form of self- report and there-
fore a source of potential bias, including those of social 
desirability, and those arising from selective recall and the 
duration of the recall period.28 Two studies included in 
this review which measured adherence through partic-
ipant self- report, sought to compare their subjective 
measurements of adherence with serum measurements 
of either drug- reactivity units or a medication’s anticoag-
ulant effect.13 23 One study showed that serum measure-
ment of the medication’s anticoagulant effect was similar 
between both the intervention and comparator groups, 
despite adherence measures being better in the interven-
tion group.23 The other study revealed that drug- reactivity 
units were worse in the intervention group than in the 
control group, which conflicted with measured adher-
ence outcome data.13 However, the presence of a drug 
biomarker does not equate to compliance and the 
absence does not equate to non- compliance.29 Indeed, 
drug metabolism should be taken into account for such 
measures of medication adherence, as physiological state 
and metabolic rate vary among individuals.30
Publication bias
A funnel plot of effect size estimates of each of the studies 
included in the meta- analysis is provided in online supple-
mentary efigure 1. Formal analysis of plot symmetry was 
not performed owing to the total number of studies 
included being less than 10.31 Visual inspection reveals 
moderate symmetry of the plot.
DISCuSSIOn
Principal findings
We conducted a rigorous systematic review of the litera-
ture to investigate whether mobile device apps demon-
strate efficacy in supporting medication adherence. A 
random- effects meta- analysis of the pooled results from 
all nine studies indicated that people who use medication 
reminder apps are significantly more likely to adhere to 
their medications than those who do not, but the results 
should be interpreted with caution owing to the data for 
six of the nine studies included in the meta- analysis being 
based on self- reported measures of adherence.
Intervention effects reported between the studies 
varied, as shown in the forest plot (figure 2). All nine 
studies reported that their mobile app- delivered inter-
ventions demonstrated efficacy in supporting medication 
adherence, although in five studies the interventions did 
not have a statistically significant effect.12 13 16 22 25 Although 
the I2 measure of statistical heterogeneity was low, and 
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meta- regression of the BCTs used by the studies was not 
able to account for variance in effect observed between 
studies, there are other potential sources of methodolog-
ical and clinical heterogeneity which may account for 
this. One potential explanation might be the variation in 
adherence measurement. This may be illustrated by three 
studies which incorporated five of the same BCTs,23–25 but 
where one23 reported notably better medication adher-
ence (OR 10.633, 95% CI 2.339 to 48.344) than the other 
two (OR 1.946, 95% CI 1.094 to 3.461; OR 1.251, 95% CI 
0.612 to 2.559).24 25 In Labovitz et al’s23 study, medication 
adherence was measured by pill counts at clinic follow- up 
visits, whereas in the other two studies adherence was 
measured by retrospective self- scoring on a medication 
adherence scale.24 25 It could be argued that both of these 
different measures of adherence are vulnerable to bias, 
with pill counts potentially being vulnerable to expecta-
tion bias and retrospective self- scores being vulnerable to 
recall bias. We subsequently performed a focused meta- 
analysis of the five studies which measured adherence 
using the Morisky Medication Adherence Scale to inves-
tigate whether this influenced the effect size observed. 
While the result of the meta- analysis remained signifi-
cant, the effect size was lower. This may support the use 
of real- time or prospective adherence monitoring over 
retrospective self- report for future research in the field of 
medication adherence.
A further possible explanation for variance in effect 
size might be the techniques, beyond those reported in 
the BCT taxonomy, used by the apps. For example, in the 
study by Labovitz et al,23 the app intervention employed 
artificial intelligence to identify the participant, their 
medication and ingestion of the medication, using the 
camera of the mobile device and software algorithms. 
This could be regarded as a highly tailored intervention, 
and one might hypothesise that the degree of tailoring 
could influence the effect size observed. A further 
example of a highly tailored intervention was seen in the 
study by Lakshminarayana et al.24 All of the app- based 
interventions in the included studies were tailored to 
the prescribed medication regimen, but in this instance 
the tailoring went beyond the prescribed medication 
regimen, to include tailoring to the patients’ intentional 
and non- intentional non- adherence, beliefs about taking 
medications, mood, cognitive impairment, symptom 
control, quality of life, age and disease duration. A signif-
icant effect size was observed in this study, and this may 
support a hypothesis that highly tailored apps are more 
effective at supporting medication adherence than mini-
mally tailored apps.
Further participant- related factors which may have 
contributed to variance in the effect size seen between 
studies, include disease burden, non- adherence 
behaviours, perceived benefit from the medication and 
any side effects. Interpretation of the overall result of the 
meta- analysis and generalisability to the wider population 
should therefore be cautious.
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Strengths and weaknesses of the primary studies
Based on the assessment of the risk of bias undertaken 
as part of this review, the evidence included in this meta- 
analysis is of moderate quality. The most common weak-
nesses in this evidence are small sample size, lack of 
objectivity of the outcome measurement, lack of blinding 
of participants and personnel, and limited follow- up time.
Strengths and weaknesses at review level
Our comprehensive literature search and search of the 
PROSPERO database indicate this is the first systematic 
review and meta- analysis to investigate the efficacy of 
mobile apps in supporting medication adherence. This 
offers new knowledge to the field; however, as such there 
are no comparable studies with which the results of this 
review can be compared.
The pooling of data from a group of studies which used a 
variety of methods for measurement of medication adher-
ence and targeted at patients with different healthcare prob-
lems is a limitation of this review. As further studies in this 
field are published, it will become more feasible to conduct 
subgroup analysis or meta- regression analyses against 
variables such as age, health condition, targeted medica-
tion, intervention content and app characteristics. A stan-
dardised protocol for measuring adherence and reporting 
the content and characteristics of app interventions may 
facilitate further analysis of the latter two variables.
This review cannot report on the likely sustainability of 
the effect on medication adherence given the short study 
duration of the studies included in this review; across the 
nine studies, the maximum follow- up period was 16 weeks. 
Furthermore, the optimal frequency and duration of app 
use that are required to achieve improvements in medica-
tion adherence are not known. Long- term and large- scale 
research is required in this field to address the question 
regarding the sustainability of the observed effect found in 
this meta- analysis.
This systematic review and meta- analysis included studies 
with a range of ages of participants. The lowest mean age 
of participants in the included studies was 20.9 years and 
the highest was 70.9 years. The ubiquity and use of mobile 
devices vary across age groups,7 and while the majority of 
participants in these studies were aged 50 and over further 
research to establish the acceptability and usability of adher-
ence apps among different age groups of adults would be 
valuable.
Finally, the reviewers set out to perform a meta- regression 
of the BCTs used by app interventions in the included 
studies.11 However, this did not reveal any significant associ-
ation between the BCTs used and the observed effect size. 
This may be owing to the low estimate of heterogeneity and 
the small number of eligible included studies.
COnCluSIOnS
This meta- analysis indicates that medication adherence 
interventions delivered by smartphone apps are asso-
ciated with higher levels of self- reported adherence to 
prescribed medications. However, when considering 
whether to recommend an app to patients, these results 
should be interpreted with caution owing to variance in 
effect size seen between the studies, the small sample sizes 
taken from different patient populations, the heteroge-
neity among included studies and the prominence of 
self- reported scales to measure medication adherence. 
Further research should aim to first establish a standard 
protocol for measuring and reporting of adherence in the 
context of evaluating digital interventions. Subsequently, 
further research investigating intervention characteristics 
associated with an app’s effect and the sustainability of 
any effect gained would add to this field.
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